Particle3D is a Danish MedTech company founded on proprietary technology to 3D print patient-fitted, natural and degradable bone implants. This enables faster ingrowth of bone tissue, remodeling into real living bone, and results in fewer complications. The technology can also be used for 3D printed implants with additives, such as antibiotics or other drugs, and even in industries outside healthcare. Good pre-clinical proof from laboratory testing in cell culture and in five separate animal trials (three in mice, two in pigs) demonstrates that P3D Bone implants perform as well as predicted. The implants are mechanically strong and free from contaminants. They have also been shown to support the rapid formation of new vascularized bone and to integrate with neighboring bone in vivo. These results have been published in well-recognized scientific papers.
Particle3D has received several awards for developing this technology (e.g. the Danish Venture Cup 2017 and the Best Danish Health Tech Startup in the Nordic Startup Awards 2019) and has received grants from Novo Nordisk Foundation and InnoBooster.
“We joined NOME to get help on regulatory issues, as well as input on product commercialization and go-to-market strategy from experienced mentors that have been through this process before themselves.”
Developed at Southern Denmark University, the company is led by CEO Thea Wulff Olesen, who has extensive experience growing life science startups, supported by two of the co-founders Casper Slots and Martin Bonde Jensen, further key employees, an independent board of directors and scientific advisors. Particle3D is located in Odense, Denmark, and joined NOME in 2018.